Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis

Year: 2023

Type: article

Abstract: To compare the immunopathology of immune checkpoint inhibitor-induced myasthenia gravis (ICI-MG) and idiopathic MG, we profiled the respective AChR autoantibody pathogenic properties. Of three ICI-MG patients with AChR autoantibodies, only one showed complement activation and modulation/blocking potency, resembling idiopathic MG. In contrast, AChR autoantibody-mediated effector functions were not detected in the other two patients, questioning the role of their AChR autoantibodies as key mediators of pathology. The contrasting properties of AChR autoantibodies in these cases challenge the accuracy of serological testing in establishing definite ICI-MG diagnoses and underscore the importance of a thorough clinical assessment when evaluating ICI-related adverse events.

Source: Annals of Clinical and Translational Neurology

DOI: 10.1002/acn3.51761

Authors: Gianvito Masi, Minh C. Pham, Tabitha Karatz, Sangwook Oh, Aimee S. Payne, Richard J. Nowak, James F. Howard, Jeffrey T. Guptill, Vern C. Juel, Kevin C. O'Connor

Institutions: Yale University, Duke University, Duke Medical Center, University of Pennsylvania, University of North Carolina at Chapel Hill

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,850

Awards: G1275810520, G33247875, Mechanisms of autoantibody production in myasthenia gravis, G4279768677, G6516119152, Molecular determinants driving diverse mechanisms of antibody-mediated pathology, Rare Disease Network for Myasthenia Gravis, Data Management and Coordinating Center: Rare Diseases Clinical Research Network, Yale Clinical and Translational Science Award, Mechanisms of autoimmunity in myasthenia gravis

OpenAlex ID: W4327595071